We are translating the breakthrough discovery of egg precursor (EggPC℠) cells into transformative treatments for female infertility.
These treatments have the potential to impact medical conditions for which there are currently few or no treatment options.
OvaPrime is a potential fertility treatment that could help restore a woman’s egg production. With OvaPrime, a woman’s own EggPC cells are isolated from a niche within her ovary where they are quiescent and repositioned such that they receive the appropriate signals to mature in vivo into new, fertilizable eggs.
OvaPrime is currently in development, and is designed to address the substantial unmet need among women suffering from premature ovarian insufficiency (POI) or poor ovarian response (POR). Women with POI or POR make few or no eggs, and as a result, are poor candidates for in vitro fertilization (IVF), which is currently the standard of care for treating infertility. Success rates with IVF have been estimated to be as low as 6% in this difficult-to-treat patient population, as compared to 28% for the broader IVF population. Many patients diagnosed with POR or POR resort to donor egg or adoption, and many give up on having a child altogether. Today, we estimate that POI and/or POR affects approximately 600,000 women per year undergoing IVF. OvaPrime has the potential to address this serious unmet need by restoring egg production as a prelude to IVF, thereby increasing the likelihood of successful outcomes and enabling women to have their own genetic children.
OvaTure is a potential fertility treatment that eliminates the need for ovarian hormone stimulation typically required as part of standard IVF. With OvaTure, a woman’s own EggPC cells are isolated from her ovary and matured in vitro into new, fertilizable eggs.
OvaTure is currently in development, and is designed to address the significant discomfort, emotional distress, and maternal morbidity associated with the ovarian hormone stimulation phase of a standard IVF cycle. Under standard IVF, hormone medications are typically used for approximately 8 to 14 days to stimulate follicular development and require both daily self-injections and multiple clinic visits for monitoring. The physical side effects range from enlarged ovaries and abdominal pain to nausea, vomiting, diarrhea and depression. One to three percent of patients suffer from Severe Ovarian Hyperstimulation Syndrome (OHSS), which may result in complications such as multiple organ dysfunction and even death. For the 1.9 million women per year undergoing standard, OvaTure has the potential to revolutionize the treatment landscape by eliminating the need for controlled ovarian stimulation.
AUGMENT is a fertility treatment designed to improve embryo development and pregnancy rates. With AUGMENT, mitochondria from a woman’s own EggPC cells are isolated and injected into the egg during IVF.
AUGMENT is currently offered to patients through an exclusive license to IVF Japan Group in Japan.